1 / 4

Prevention of Diabetes

Prevention of Diabetes. Key Messages As safe and effective preventive therapies for type 1 diabetes have not yet been identified, any attempts to prevent type 1 diabetes should be undertaken only within the confines of formal research protocols.

min
Télécharger la présentation

Prevention of Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prevention of Diabetes Key Messages • As safe and effective preventive therapies for type 1 diabetes have not yet been identified, any attempts to prevent type 1 diabetes should be undertaken only within the confines of formal research protocols. • Intensive and structured lifestyle modification that results in loss of approximately 5% of initial body weight can reduce the risk of progression from impaired glucose tolerance to type 2 diabetes by almost 60%.

  2. Prevention of Diabetes Key Messages • Progression from prediabetes to type 2 diabetes can also be reduced by pharmacologic therapy with metformin (~30% reduction), acarbose (~30% reduction) and thiazolidinedione (~60% reduction).

  3. Prevention of Diabetes 2008 CPG Recommendations • A structured program of lifestyle modification that includes moderate weight loss and regular physical activity should be implemented to reduce the risk of type 2 diabetes in individuals with IGT [Grade A, Level 1A (12,13)] and IFG [Grade D, Consensus].

  4. Prevention of Diabetes 2008 CPG Recommendations • In individuals with IGT, pharmacologic therapy with a biguanide (metformin) [Grade A, Level 1A (13)] or an alpha-glucosidase inhibitor [Grade A, Level 1A (19)] should be considered to reduce the risk of type 2 diabetes. In individuals with IGT and/or IFG and no known cardiovascular disease, treatment with a thiazolidinedione could be considered to reduce the risk of type 2 diabetes [Grade A, Level 1A (23)].

More Related